{"log_id": 8466823380803539987, "direction": 0, "words_result_num": 31, "words_result": [{"probability": {"variance": 6e-06, "average": 0.99876, "min": 0.990138}, "location": {"width": 778, "top": 157, "height": 59, "left": 281}, "words": "根据临床研究的结果,对患者除了仔细的医疗处置和监测外通常不需要进行"}, {"probability": {"variance": 6e-06, "average": 0.998798, "min": 0.992161}, "location": {"width": 193, "top": 204, "height": 38, "left": 234}, "words": "特殊的实验室评价"}, {"probability": {"variance": 0.000151, "average": 0.996002, "min": 0.955239}, "location": {"width": 290, "top": 254, "height": 40, "left": 231}, "words": "本品和阿那白滞素联合治疗"}, {"probability": {"variance": 2e-06, "average": 0.999299, "min": 0.99275}, "location": {"width": 777, "top": 303, "height": 57, "left": 277}, "words": "在对同时接受本品和阿那白滞素治疗的患者进行研究时发现与单独使用本"}, {"probability": {"variance": 0, "average": 0.999462, "min": 0.997687}, "location": {"width": 822, "top": 350, "height": 57, "left": 228}, "words": "品相比,同时使用本品和阿那白滞素治疗时严重感染的发生率更高,并且有2%"}, {"probability": {"variance": 0.003462, "average": 0.983543, "min": 0.632498}, "location": {"width": 799, "top": 397, "height": 59, "left": 229}, "words": "3139)的患者出现中性粒细胞减少(绝对中性粒细胞计数<1000/m3)。其中"}, {"probability": {"variance": 9e-06, "average": 0.998646, "min": 0.983405}, "location": {"width": 825, "top": 444, "height": 61, "left": 223}, "words": "名患者并发蜂窝组织炎,经住院治疗后康复(参见“注意事项”和“药物相互作"}, {"probability": {"variance": 0.000101, "average": 0.986118, "min": 0.975378}, "location": {"width": 54, "top": 494, "height": 28, "left": 222}, "words": "用”)"}, {"probability": {"variance": 0, "average": 0.999527, "min": 0.998623}, "location": {"width": 83, "top": 541, "height": 30, "left": 228}, "words": "【禁忌】"}, {"probability": {"variance": 1e-06, "average": 0.999147, "min": 0.996996}, "location": {"width": 431, "top": 590, "height": 46, "left": 264}, "words": "对本品活性成份或制剂中其他成份过敏者"}, {"probability": {"variance": 5e-06, "average": 0.998526, "min": 0.991466}, "location": {"width": 385, "top": 638, "height": 43, "left": 261}, "words": "败血症患者或存在败血症风险的患者"}, {"probability": {"variance": 1.1e-05, "average": 0.997962, "min": 0.987883}, "location": {"width": 481, "top": 685, "height": 47, "left": 260}, "words": "包括慢性或局部感染在内的严重活动性感染患"}, {"probability": {"variance": 0, "average": 0.999473, "min": 0.998153}, "location": {"width": 133, "top": 730, "height": 34, "left": 216}, "words": "【注意事项】"}, {"probability": {"variance": 0, "average": 0.997414, "min": 0.997414}, "location": {"width": 33, "top": 721, "height": 36, "left": 962}, "words": "司"}, {"probability": {"variance": 1.1e-05, "average": 0.997461, "min": 0.991855}, "location": {"width": 100, "top": 778, "height": 30, "left": 207}, "words": "特别警告"}, {"probability": {"variance": 0, "average": 0.993035, "min": 0.993035}, "location": {"width": 82, "top": 786, "height": 84, "left": 958}, "words": "★"}, {"probability": {"variance": 0.005061, "average": 0.985169, "min": 0.596227}, "location": {"width": 842, "top": 823, "height": 76, "left": 254}, "words": "曾有使用本品发生严重感染(包括脓毒血症和结核病)的报告些是致命"}, {"probability": {"variance": 0.004225, "average": 0.969033, "min": 0.770465}, "location": {"width": 860, "top": 864, "height": 79, "left": 200}, "words": "感染。这些感染是由于细菌、分杆菌、真菌,病毒和寄生虫(包括原"}, {"probability": {"variance": 0.001404, "average": 0.987195, "min": 0.798908}, "location": {"width": 830, "top": 911, "height": 79, "left": 200}, "words": "的。也曾有机会致病菌感染的报(包括军团菌属和利斯塔氏菌属)。需要对在"}, {"probability": {"variance": 0.002838, "average": 0.982991, "min": 0.785627}, "location": {"width": 831, "top": 964, "height": 68, "left": 198}, "words": "本品治疗过程中出现新发感染的患者进行严密监测。如果患者出现严重感染必须"}, {"probability": {"variance": 0.004712, "average": 0.985913, "min": 0.586753}, "location": {"width": 828, "top": 1013, "height": 65, "left": 196}, "words": "停止使用本品。复发性成慢性感染的患者或存在可能导致患者易受感染的潜在条"}, {"probability": {"variance": 0.000368, "average": 0.991845, "min": 0.921326}, "location": {"width": 434, "top": 1065, "height": 42, "left": 194}, "words": "件,当考虑使用本品治疗时,应谨慎使用"}, {"probability": {"variance": 7e-06, "average": 0.998444, "min": 0.98881}, "location": {"width": 780, "top": 1112, "height": 61, "left": 242}, "words": "本品和阿那滞素( Anakinra)联合治疗与严重感染和中性粒细胞减少症的"}, {"probability": {"variance": 0.000476, "average": 0.994273, "min": 0.868557}, "location": {"width": 829, "top": 1158, "height": 61, "left": 189}, "words": "风险增加有关。由于并未证实该联合治疗可以增加临床疗效,因此不推荐本品和"}, {"probability": {"variance": 2e-06, "average": 0.998869, "min": 0.996378}, "location": {"width": 219, "top": 1209, "height": 35, "left": 190}, "words": "阿那白滞素联合使用"}, {"probability": {"variance": 3.9e-05, "average": 0.995133, "min": 0.973852}, "location": {"width": 776, "top": 1255, "height": 60, "left": 239}, "words": "一项在180例标准治疗(包括环磷酰胺和大剂量激素)上加用本品的 Wegener"}, {"probability": {"variance": 9e-06, "average": 0.998626, "min": 0.983182}, "location": {"width": 831, "top": 1302, "height": 60, "left": 183}, "words": "肉芽肿患者的安慰剂对照研究中,与单用标准治疗相比,加用本品组患者的临床"}, {"probability": {"variance": 7e-06, "average": 0.998117, "min": 0.988522}, "location": {"width": 828, "top": 1350, "height": 59, "left": 183}, "words": "症状未改善更佳。本品治疗组患者与安慰剂组相比,发生各型非上皮恶性肿瘤更"}, {"probability": {"variance": 0.000176, "average": 0.995426, "min": 0.943055}, "location": {"width": 480, "top": 1398, "height": 46, "left": 183}, "words": "多。不推荐 Wegener肉芽肿患者使用本品治疗"}, {"probability": {"variance": 6e-06, "average": 0.998447, "min": 0.989322}, "location": {"width": 778, "top": 1447, "height": 57, "left": 230}, "words": "在一项48例使用本品或安慰剂治疗的中度到重度酒精性肝炎住院患者中进"}, {"probability": {"variance": 1e-06, "average": 0.999081, "min": 0.994635}, "location": {"width": 827, "top": 1493, "height": 57, "left": 178}, "words": "行的试验表明,本品治疗无效,且治疗6个月后,本品治疗组患者的死亡率明显"}], "language": 3}